Gong 2019.

Methods	Study design: Randomised clinical trial Study duration: January 2015 to June 2016 Duration of follow‐up: 3 years Setting: Hospital
Participants	Number of participants: 98 Inclusion criteria: Diagnosed as HCC; TNM Ⅲ‐Ⅳ stage; tumour diameter > 5 cm Age (mean ± SD, range ): TACE + MWA: 58.1 ± 7.9 years; TACE alone: 57.5 ± 7.1 years Male (n/total): TACE + MWA: 29/49; TACE alone: 28/49
Interventions	TACE + RFA group (n = 49): TACE: TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: theprubicin, fluorouracil, and oxaliplatin MWA: The interval between TACE and MWA was 14 days. Output power of 50‐70 W Control group (n = 49): TACE comprised of hepatic arterial infusion chemotherapy and hepatic artery embolisation Chemotherapeutic drugs: theprubicin, fluorouracil, and oxaliplatin
Outcomes	Tumour response: measured by contrast‐enhanced CT at 1 month after treatment Immunological function: measured by blood testing The level of AFP: measured by blood testing
Notes	Country of study: China Source of funding: None There was insufficient information available to satisfactorily determine the method of randomisation and the study data could not be verified. We have attempted to contact the study authors for more information, but so far, we have not been successful in doing this.